Medical Crossfire®: Transitioning From Pediatric to Adult SMA Care Teams: How Do We Optimize Outcomes as Patients Age?

Released On
March 31, 2020

Expires On
March 31, 2021

Media Type

Completion Time
60 minutes

Case Management, Genetics, Neurology, Pediatrics, Physiatry, Primary Care

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

Supported by an educational grant from Biogen.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Nurses — maximum of 1.5 Contact Hour(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed toward neurologists, specialty nurse practitioners, specialty physician assistants, family physicians/primary care physicians, pediatricians, and additional healthcare providers who are involved in the treatment and management of SMA, such as pulmonologists, respiratory therapists, psychiatrists, pediatricians, and OBGYNs.

Program Overview

Spinal muscular atrophy (SMA) is a rare, inherited disease characterized by limited function and mobility and a wide range of disease severity. The availability of new therapeutic options has improved life expectancy for pediatric patients, but as they transition to adult medical care, they are met with several health needs and barriers to health services. This Medical Crossfire®: Transitioning From Pediatric to Adult SMA Care Teams: How Do We Optimize Outcomes as Patients Age? addresses the lack of best-practice models when caring for patients with SMA who are transitioning out of the pediatric setting. The experts share their clinical experience with patients as they age and the challenges that patients and their families face as they transition to adult medical care. They also discuss the clinical features and diagnosis of SMA, current standards of care and data from clinical studies, and the importance of multidisciplinary care teams.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Recognize the clinical features of the different forms of SMA, including the more subtle characteristics of adult-onset disease.
  • Integrate genetic testing into clinical practice for patients with suspected SMA.
  • Evaluate appropriate therapies for pediatric and adult patients with SMA based on available efficacy and safety data of current and emerging therapies.
  • Develop team-based strategies to improve transition of care in patients with SMA as they age.


Claudia A. Chiriboga, MD, MPH, FAAN

Claudia A. Chiriboga, MD, MPH, FAAN

Professor of Neurology and Pediatrics
Division of Pediatric Neurology, Department of Neurology
Columbia University Medical Center
Director, Pediatric MDA Care Clinic
Pediatric Neuromuscular Division
New York, NY

W. David Arnold, MD

W. David Arnold, MD

Associate Professor
Division of Neuromuscular Diseases
Department of Neurology
The Ohio State University Wexner Medical Center
Columbus, OH

Vanessa Battista, RN, M.S., CPNP-PC, CHPPN

Vanessa Battista, RN, M.S., CPNP-PC, CHPPN

Pediatric Nurse Practitioner
Division of Neurology, Neuromuscular Program
The Children's Hospital of Philadelphia
Philadelphia, PA

Oscar Henry Mayer, MD

Oscar Henry Mayer, MD

Medical Director, Pulmonary Function Testing Laboratory
Division of Pulmonology
The Children’s Hospital of Philadelphia
Professor of Pediatrics
The Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Disclosures of Conflicts of Interest

Claudia A. Chiriboga, MD, MPH, FAAN

  • Grant/Research Support: NIH, AveXis, Roche, Biogen;
  • Consultant: Biogen, AveXis, Cytokinetics, Roche, Cencute;
  • Speaker’s Bureau: Biogen

W. David Arnold, MD

  • Grant/Research Support: NIH, NMD Pharma;
  • Consultant: Genentech, Roche

Vanessa Battista, RN, M.S., CPNP-PC, CHPPN

  • Speaker’s Bureau: AveXis

Oscar Henry Mayer, MD

  • Oscar Henry Mayer, MD, has no relevant financial relationships with commercial interests.

The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Video” will be available for your reference.
  • In order to receive a CME/CE Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.